dalteparin has been researched along with Branch Vein Occlusion in 12 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In recent-onset branch retinal vein occlusion, no significant difference was found in the final visual acuity between the patients treated by dalteparin or aspirin." | 9.13 | Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial. ( Farahvash, MM; Farahvash, MS; Mirshahi, A; Mohammadzadeh, S; Moradimogadam, M, 2008) |
| "To compare the long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion with that of aspirin." | 9.13 | Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion. ( Farahvash, MM; Farahvash, MS; Mohammadzadeh, S; Moradimogadam, M, 2008) |
| "The present study assessed the therapeutic effects of dalteparin in patients who had recent onset central retinal vein occlusion (CRVO) as compared with those of acetylsalicylic acid (ASA)." | 9.13 | Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid. ( Farahvash, MS; Moghaddam, MM; Moghimi, S; Mohammadzadeh, S, 2008) |
| "Nonischemic CRVO with cystoid macular edema was diagnosed and an intravitreal injection of ranibizumab was performed." | 5.72 | Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report. ( Biskup, M; Kal, M; Krupińska, J; Odrobina, D; Płatkowska-Adamska, B, 2022) |
| "In recent-onset branch retinal vein occlusion, no significant difference was found in the final visual acuity between the patients treated by dalteparin or aspirin." | 5.13 | Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial. ( Farahvash, MM; Farahvash, MS; Mirshahi, A; Mohammadzadeh, S; Moradimogadam, M, 2008) |
| "To compare the long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion with that of aspirin." | 5.13 | Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion. ( Farahvash, MM; Farahvash, MS; Mohammadzadeh, S; Moradimogadam, M, 2008) |
| "The present study assessed the therapeutic effects of dalteparin in patients who had recent onset central retinal vein occlusion (CRVO) as compared with those of acetylsalicylic acid (ASA)." | 5.13 | Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid. ( Farahvash, MS; Moghaddam, MM; Moghimi, S; Mohammadzadeh, S, 2008) |
| "In the THRIVE Treatment study, no patient suffered from a recurrent VTE, but 1 patient randomised to enoxaparin/warfarin experienced major bleeding." | 5.12 | Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. ( Harenberg, J; Jörg, I; Weiss, C, 2006) |
| "We present a case of protein S deficiency causing central retinal vein occlusion treated with anticoagulation, which includes heparin followed by oral warfarin therapy." | 3.74 | Central retinal vein occlusion secondary to protein S deficiency. ( Barampouti, F; Yap, YC, 2007) |
| "In 19 cases central retinal vein occlusion was observed and retinal branch vein occlusion in 11 cases." | 2.69 | [Evaluation of fraxiparine efficacy in the treatment of retinal vein occlusion]. ( Bieroń, K; Goszcz, A; Grodzińska, L; Kostka-Trabka, E; Romanowska, B, 1999) |
| "Nonischemic CRVO with cystoid macular edema was diagnosed and an intravitreal injection of ranibizumab was performed." | 1.72 | Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report. ( Biskup, M; Kal, M; Krupińska, J; Odrobina, D; Płatkowska-Adamska, B, 2022) |
| "Four (4) central retinal vein occlusions in 3 patients, 4 branch retinal vein occlusions in 4 patients, and 1 superior orbital vein occlusion in 1 patient were treated with subcutaneous (SC) enoxaparin 100 IU/kg twice a day." | 1.35 | Retinal and orbital venous occlusions treated with enoxaparin. ( Angelis, MD; Belcaro, G; Cesarone, MR; Ciucci, F; Lofoco, G; Nebbioso, M; Pascarella, A; Quercioli, P; Rapagnetta, L; Steigerwalt, RD, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Pinna, A | 1 |
| Simula, P | 1 |
| Zinellu, A | 1 |
| Romanowska, B | 1 |
| Goszcz, A | 1 |
| Grodzińska, L | 1 |
| Bieroń, K | 1 |
| Kostka-Trabka, E | 1 |
| Ageno, W | 1 |
| Cattaneo, R | 1 |
| Manfredi, E | 1 |
| Chelazzi, P | 1 |
| Venco, L | 1 |
| Ghirarduzzi, A | 1 |
| Cimino, L | 1 |
| Filippucci, E | 1 |
| Ricci, AL | 1 |
| Romanelli, D | 1 |
| Incorvaia, C | 1 |
| D'Angelo, S | 1 |
| Campana, F | 1 |
| Molfino, F | 1 |
| Scannapieco, G | 1 |
| Rubbi, F | 1 |
| Imberti, D | 1 |
| Płatkowska-Adamska, B | 1 |
| Kal, M | 1 |
| Krupińska, J | 1 |
| Biskup, M | 1 |
| Odrobina, D | 1 |
| Dragoni, F | 1 |
| Kaarniranta, K | 1 |
| Steigerwalt, RD | 1 |
| Cesarone, MR | 1 |
| Belcaro, G | 1 |
| Quercioli, P | 1 |
| Lofoco, G | 1 |
| Ciucci, F | 1 |
| Pascarella, A | 1 |
| Angelis, MD | 1 |
| Rapagnetta, L | 1 |
| Nebbioso, M | 1 |
| Harenberg, J | 1 |
| Jörg, I | 1 |
| Weiss, C | 1 |
| Yap, YC | 1 |
| Barampouti, F | 1 |
| Farahvash, MS | 3 |
| Moradimogadam, M | 2 |
| Farahvash, MM | 2 |
| Mohammadzadeh, S | 3 |
| Mirshahi, A | 1 |
| Aggermann, T | 1 |
| Haas, P | 1 |
| Binder, S | 1 |
| Moghaddam, MM | 1 |
| Moghimi, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Parnaparin Versus Aspirin in the Treatment of Retinal Vein Occlusion. A Randomized, Double Blind, Controlled Study[NCT00732927] | Phase 3 | 67 participants (Actual) | Interventional | 2002-07-31 | Terminated (stopped due to slow recruitment rate) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 trials available for dalteparin and Branch Vein Occlusion
| Article | Year |
|---|---|
Subcutaneous nadroparin calcium in the treatment of recent onset retinal vein occlusion: a pilot study.
Topics: Aged; Anticoagulants; Data Interpretation, Statistical; Female; Humans; Injections, Subcutaneous; La | 2012 |
[Evaluation of fraxiparine efficacy in the treatment of retinal vein occlusion].
Topics: Adult; Aged; Angiography; Anticoagulants; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nadr | 1999 |
Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study.
Topics: Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female | 2010 |
Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
Topics: Administration, Oral; Anticoagulants; Arteries; Azetidines; Benzylamines; Drug Therapy, Combination; | 2006 |
Dalteparin versus aspirin in recent-onset branch retinal vein occlusion: a randomized clinical trial.
Topics: Aspirin; Dalteparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Retinal Vein Occlusion; | 2008 |
Long-term effect of dalteparin in the prevention of neovascularization of iris in recent-onset central retinal vein occlusion.
Topics: Aspirin; Dalteparin; Female; Fibrinolytic Agents; Humans; Iris; Male; Middle Aged; Neovascularizatio | 2008 |
Dalteparin in the management of recent onset central retinal vein occlusion: a comparison with acetylsalicylic acid.
Topics: Administration, Oral; Aspirin; Dalteparin; Female; Fibrinolytic Agents; Humans; Injections, Subcutan | 2008 |
5 other studies available for dalteparin and Branch Vein Occlusion
| Article | Year |
|---|---|
Central Retinal Vein Occlusion After Discontinuation of Rivaroxaban Therapy in a Young Patient with COVID-19 Pulmonary Embolism: A Case Report.
Topics: Adult; Angiogenesis Inhibitors; COVID-19; COVID-19 Serotherapy; Enoxaparin; Glucocorticoids; Humans; | 2022 |
Individual benefits of enoxaparin treatment in branch vein occlusion.
Topics: Aged; Enoxaparin; Fibrinolytic Agents; Humans; Injections, Subcutaneous; Macular Edema; Male; Middle | 2018 |
Retinal and orbital venous occlusions treated with enoxaparin.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Enoxaparin; Female; Humans; Injections | 2008 |
Central retinal vein occlusion secondary to protein S deficiency.
Topics: Adult; Anticoagulants; Enoxaparin; Follow-Up Studies; Humans; Male; Protein S Deficiency; Retinal He | 2007 |
Central retinal vein occlusion as a possible presenting manifestation of Sneddon syndrome.
Topics: Dalteparin; Fibrinolytic Agents; Fundus Oculi; Humans; Livedo Reticularis; Male; Middle Aged; Pentox | 2007 |